Biomedical literature, made navigable
Discover articles through diseases, drugs, treatments, interventions, clinical instruments, institutions and funders extracted from the BMJ open corpus.
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsChoose an entity to see the articles in which it was identified.
…, betamethasone), oral hydroxychloroquine (200 mg twice daily), mycophenolate mofetil (1 g twice daily), emollients, sunscreen, and functional physio…
…h high baseline serum IgA2 anti-dsDNA antibodies, compared with rituximab alone. This biomarker-enrichment trial was developed from the i…
…A 1:1280, anti-dsDNA positive, low C3/C4). Initial therapy with hydroxychloroquine (200 mg/day) and low-dose prednisone (7.5 mg/day) achieved clin…
… 4.0 (https://creativecommons.org/licenses/by/4.0/).Conclusions Anifrolumab demonstrates consistent efficacy across CLE subtypes, and an ac…
…eater extent in SRI-4 responders vs non-responders ( figure 1). Cenerimod 2 mg showed less pronounced effects; placebo showed minimal cha…
…tibody positivity and low complement levels.Among patients with glomerular hematuria (n= 137), independent predictors of clinically significant LN i…
…study investigated the relationship between a methylation-based SLE risk score (MRS), a non-HLA SLE polygenic risk score (SLE-PRS),…
…ng to sustained drug-free disease control in severe, refractory SLE. Phase 2 Breakfree-SLE trial ( NCT07015983) is currently enroll…
…tment platelet reactivity to prasugrel, even after doubling the prasugrel dose. This case highlights rare resistance to newer P2Y12 inhib…
…n 85 mg/m² every 3 weeks), lenvatinib (8 mg/day from Day 5) and Adebrelimab (1200 mg on Day 3, every 3 weeks) for 2–4 cycles. Surgery eligi…
…e whole genome sequencing (WGS) data from the FEVR cases in the Genomics England (GEL) 100 000 genomes project to identify the causative variant…
…EN and related WHO guidance.Methods and analysis We will search PubMed, Web of Science, Cochrane Library and Google Scholar for studie…